Brain cancer vaccine shows promise in early trial

This study tested a personalized vaccine made from a patient's own tumor cells and immune cells (dendritic cells) for people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to see if the vaccine is safe and can help delay tumor growth. 76 participants received the vaccine after standard surgery and chemoradiation. The treatment aims to train the immune system to attack remaining cancer cells, potentially improving outcomes without major side effects.